Scholarlink

<p>While advances in the understanding of tumor biology through multi-omics profiling hold the promise of substantially improving patient outcomes, the cost implications of such strategies remain unclear. We therefore performed a comparative cost analysis of patients treated either within the Tumor Profiler (TuPro) melanoma project or from a control cohort who received treatment after standard next-generation sequencing testing. After adjustment of cohorts through inverse probability of treatment weighting, we found no evidence of statistically significant differences in total costs between the two cohorts (95% confidence interval −10% to +67%). Importantly, treatment costs (95% confidence interval −28% to +41%) were similar between the two cohorts. In conclusion, we found no evidence that treatment recommendations guided by advanced multi-omics profiling led to significantly higher treatment costs in a Swiss context.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative cost analysis of a diagnostic multi-omics platform for decision support in advanced cancer – results from the Tumor Profiler Melanoma project

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月17日

查看全文
  • Tarun Mehra,
  • Dominik Menges,
  • Benedict Gosztonyi,
  • Nicola Miglino,
  • Alexander Ring,
  • Laura Boos,
  • Bettina Sobottka,
  • Rudolf Aebersold,
  • Melike Ak,
  • Faisal S. Al-Quaddoomi,
  • Silvana I. Albert,
  • Jonas Albinus,
  • Ilaria Alborelli,
  • Sonali Andani,
  • Per-Olof Attinger,
  • Marina Bacac,
  • Monica-Andreea Baciu-Drăgan,
  • Daniel Baumhoer,
  • Beatrice Beck-Schimmer,
  • Niko Beerenwinkel,
  • Christian Beisel,
  • Lara Bernasconi,
  • Anne Bertolini,
  • Bernd Bodenmiller,
  • Ximena Bonilla,
  • Lars Bosshard,
  • Byron Calgua,
  • Ruben Casanova,
  • Stéphane Chevrier,
  • Natalia Chicherova,
  • Ricardo Coelho,
  • Maya D’Costa,
  • Esther Danenberg,
  • Natalie R. Davidson,
  • Reinhard Dummer,
  • Stefanie Engler,
  • Martin Erkens,
  • Katja Eschbach,
  • Cinzia Esposito,
  • André Fedier,
  • Pedro F. Ferreira,
  • Joanna Ficek-Pascual,
  • Anja L. Frei,
  • Bruno Frey,
  • Sandra Goetze,
  • Linda Grob,
  • Gabriele Gut,
  • Detlef Günther,
  • Pirmin Haeuptle,
  • Viola Heinzelmann-Schwarz,
  • Sylvia Herter,
  • Rene Holtackers,
  • Tamara Huesser,
  • Alexander Immer,
  • Anja Irmisch,
  • Francis Jacob,
  • Andrea Jacobs,
  • Tim M. Jaeger,
  • Alva R. James,
  • Philip M. Jermann,
  • André Kahles,
  • Abdullah Kahraman,
  • Viktor H. Koelzer,
  • Werner Kuebler,
  • Jack Kuipers,
  • Christian P. Kunze,
  • Christian Kurzeder,
  • Kjong-Van Lehmann,
  • Mitchell Levesque,
  • Ulrike Lischetti,
  • Flavio C. Lombardo,
  • Sebastian Lugert,
  • Gerd Maass,
  • Markus G. Manz,
  • Philipp Markolin,
  • Martin Mehnert,
  • Julien Mena,
  • Julian M. Metzler,
  • Nicola Miglino,
  • Emanuela S. Milani,
  • Holger Moch,
  • Simone Muenst,
  • Riccardo Murri,
  • Charlotte KY Ng,
  • Stefan Nicolet,
  • Marta Nowak,
  • Monica Nunez Lopéz,
  • Patrick GA Pedrioli,
  • Lucas Pelkmans,
  • Salvatore Piscuoglio,
  • Michael Prummer,
  • Laurie Prélot,
  • Natalie Rimmer,
  • Mathilde Ritter,
  • Christian Rommel,
  • María L. Rosano-González,
  • Gunnar Rätsch,
  • Natascha Santacroce,
  • Jacobo Sarabia del Castillo,
  • Ramona Schlenker,
  • Petra C. Schwalie,
  • Severin Schwan,
  • Tobias Schär,
  • Gabriela Senti,
  • Wenguang Shao,
  • Franziska Singer,
  • Sujana Sivapatham,
  • Berend Snijder,
  • Bettina Sobottka,
  • Vipin T. Sreedharan,
  • Stefan Stark,
  • Daniel J. Stekhoven,
  • Tanmay Tanna,
  • Alexandre PA Theocharides,
  • Tinu M. Thomas,
  • Markus Tolnay,
  • Vinko Tosevski,
  • Mustafa A. Tuncel,
  • Marina Tusup,
  • Audrey Van Drogen,
  • Marcus Vetter,
  • Tatjana Vlajnic,
  • Sandra Weber,
  • Walter P. Weber,
  • Rebekka Wegmann,
  • Michael Weller,
  • Fabian Wendt,
  • Norbert Wey,
  • Andreas Wicki,
  • Mattheus HE Wildschut,
  • Bernd Wollscheid,
  • Shuqing Yu,
  • Johanna Ziegler,
  • Marc Zimmermann,
  • Martin Zoche,
  • Gregor Zuend,
  • Viktor Hendrik Koelzer,
  • Holger Moch,
  • Nora C. Toussaint,
  • Mitchell Levesque,
  • Egle Ramelyte,
  • Johanna Mangana,
  • Reinhard Dummer,
  • Andreas Wicki

摘要

While advances in the understanding of tumor biology through multi-omics profiling hold the promise of substantially improving patient outcomes, the cost implications of such strategies remain unclear. We therefore performed a comparative cost analysis of patients treated either within the Tumor Profiler (TuPro) melanoma project or from a control cohort who received treatment after standard next-generation sequencing testing. After adjustment of cohorts through inverse probability of treatment weighting, we found no evidence of statistically significant differences in total costs between the two cohorts (95% confidence interval −10% to +67%). Importantly, treatment costs (95% confidence interval −28% to +41%) were similar between the two cohorts. In conclusion, we found no evidence that treatment recommendations guided by advanced multi-omics profiling led to significantly higher treatment costs in a Swiss context.